|
US2016194352A1
|
|
Amorphous forms of daclatasvir dihydrochloride
|
|
WO2016075617A1
|
|
Fixed dose pharmaceutical formulations of analgesic and anti-spasmodic drugs
|
|
WO2016059609A1
|
|
Acylation process for preparation of liraglutide
|
|
US2016045470A1
|
|
Amorphous solid dispersion of treprostinil diethanolamine
|
|
WO2016009401A2
|
|
Preparation of tedizolid phosphate
|
|
WO2016005960A1
|
|
Process for preparation of liraglutide
|
|
WO2016001851A1
|
|
Preparation of ticagrelor
|
|
US2015368238A1
|
|
Substituted imidazo[1,2-a]pyridine compounds as tropomyosin receptor kinase a (TrkA) inhibitors
|
|
WO2015193786A1
|
|
Method of purifying anti-idiotypic antibodies
|
|
WO2015140700A1
|
|
Cell culture process
|
|
WO2015132745A1
|
|
Method for detection of neutralizing anti-rituximab antibodies
|
|
WO2015125113A1
|
|
Method of culturing high cell density pbmc's
|
|
WO2015121784A1
|
|
Method for detection of anti-rituximab antibodies
|
|
WO2015107444A1
|
|
In-vitro assay for the assessment of post translationally modified protein isoforms
|
|
US2015141630A1
|
|
Process for preparation of iron sucrose
|
|
WO2015059679A1
|
|
Improved process for the preparation of eliglustat
|
|
WO2015044876A1
|
|
Molecular weight markers for protected polypeptides
|
|
CA2921927A1
|
|
Selectable single dose auto-injector and methods of making and using same
|
|
WO2015011659A1
|
|
Crystalline polymorphic forms of regorafenib and processes for the preparation of polymorph i of regorafenib
|
|
CA2918451A1
|
|
Process for the preparation of suvorexant and intermediates useful in the synthesis of suvorexant
|
